CA2370272A1 - Protease activated receptor 2 variants - Google Patents

Protease activated receptor 2 variants Download PDF

Info

Publication number
CA2370272A1
CA2370272A1 CA002370272A CA2370272A CA2370272A1 CA 2370272 A1 CA2370272 A1 CA 2370272A1 CA 002370272 A CA002370272 A CA 002370272A CA 2370272 A CA2370272 A CA 2370272A CA 2370272 A1 CA2370272 A1 CA 2370272A1
Authority
CA
Canada
Prior art keywords
par
polypeptide
receptor
amino acid
wild type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370272A
Other languages
English (en)
French (fr)
Inventor
Andrew Finlay Walls
Karen-Jane Palmer
Steven John Compton
Jennifer Ann Cairns
Alan Charles Gough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370272A1 publication Critical patent/CA2370272A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002370272A 1999-04-15 2000-04-17 Protease activated receptor 2 variants Abandoned CA2370272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9908513.6 1999-04-15
GBGB9908513.6A GB9908513D0 (en) 1999-04-15 1999-04-15 Molecular cloning of a new DNA sequence for protease activated receptor 2
PCT/GB2000/001455 WO2000063371A1 (en) 1999-04-15 2000-04-17 Protease activated receptor 2 variants

Publications (1)

Publication Number Publication Date
CA2370272A1 true CA2370272A1 (en) 2000-10-26

Family

ID=10851510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370272A Abandoned CA2370272A1 (en) 1999-04-15 2000-04-17 Protease activated receptor 2 variants

Country Status (7)

Country Link
EP (1) EP1165790A1 (es)
JP (1) JP2002541843A (es)
AU (1) AU4581200A (es)
CA (1) CA2370272A1 (es)
GB (1) GB9908513D0 (es)
MX (1) MXPA01010380A (es)
WO (1) WO2000063371A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3962934A4 (en) * 2019-05-03 2023-05-31 Janssen Biotech, Inc. PAR2 MODULATION AND METHOD FOR IT

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213286D0 (en) * 2002-06-10 2002-07-24 Univ Edinburgh Par-2-Activating peptide derivative and pharmaceutical composition using the same
FR2841559A1 (fr) * 2002-06-28 2004-01-02 Pfizer Recepteurs par modifies, preparation et utilisations
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
WO2012090207A2 (en) * 2010-12-30 2012-07-05 Hadasit Medical Research Services & Development Limited Par1 and par2 c-tail peptides and peptide mimetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716789A (en) * 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3962934A4 (en) * 2019-05-03 2023-05-31 Janssen Biotech, Inc. PAR2 MODULATION AND METHOD FOR IT

Also Published As

Publication number Publication date
EP1165790A1 (en) 2002-01-02
MXPA01010380A (es) 2003-07-21
GB9908513D0 (en) 1999-06-09
WO2000063371A1 (en) 2000-10-26
AU4581200A (en) 2000-11-02
JP2002541843A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
AU2002213053B2 (en) Nectin polypeptides, polynucleotides, methods of making and use thereof
US20030044409A1 (en) Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2005084116A2 (en) Calcium channel variants
JP2005521429A (ja) Ｆｃレセプターホモログ、試薬およびこれらの使用
AU2005267724A1 (en) NOTCH mutations leading to increased receptor signaling
JPH07509613A (ja) インターロイキン−１０（ｉｌ−１０）のための哺乳類レセプター
JP2002533134A (ja) ペプチドグリカン認識タンパク質
AU7608898A (en) Ntn-2 member of tnf ligand family
JP2001228137A (ja) Ｃ３ａ受容体およびＣ３ａを用いるスクリーニング方法
WO1993021302A1 (en) Cadherin materials and methods
AU2001284977A1 (en) Claudin polypeptides
EP1351968B1 (en) Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
US20030180739A1 (en) Reagents and methods for identifying gene targets for treating cancer
WO2001012658A2 (en) Human icos ligand and application thereof
US20080009004A1 (en) Claudin polypeptides, polynucleotides, and methods of making and use thereof
CA2370272A1 (en) Protease activated receptor 2 variants
US20040038370A1 (en) Claudin polypeptides
WO1998033819A9 (en) Cellular receptors for subgroup c adenoviruses and group b coxsackieviruses
EP1439223A1 (en) Novel class ii cytokine receptor
CA2316545A1 (en) Novel nucleic acid and polypeptide with homology to the tnf-receptors
US20020141999A1 (en) Ligand for CD7 and methods for use thereof
EP1385945A1 (en) Novel mutation
JPH0827190A (ja) コレシストキニン−ｂ／ガストリン受容体蛋白及び遺伝子
JP2006504407A (ja) 血管障害、異常脂質血症および関連疾患の治療用の新規治療標的
WO2001083556A2 (en) Retina xr receptor

Legal Events

Date Code Title Description
FZDE Dead